CM551 not checked

Keymed Biosciences Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive repeated subcutaneous doses of CM551 solution in a dose escalation format across 2 sequential MAD cohorts.”In the company’s words, NCT07900945 on ClinicalTrials.gov
Tested for
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Main trialPhase 1
“This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants”In the company’s words, NCT07900945 on ClinicalTrials.gov

Other drugs for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

All 102 drugs for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Sep 2027 Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CM551

Following is part of Solo: you see every change to CM551 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in